Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide, Oxaliplatin and Capecitabine in Advanced HCC
NCT00351195Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Feb 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, oxaliplatin and capecitabine in hepatocellular carcinoma (HCC), sponsored by Rigshospitalet. Primary endpoint: Response Rate. Started Feb 2006; status: terminated.
02
Drugs
etoposideoxaliplatincapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00351195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351195.